PMID- 26398389
OWN - NLM
STAT- MEDLINE
DCOM- 20160706
LR  - 20200106
IS  - 2299-5684 (Electronic)
IS  - 1734-1140 (Linking)
VI  - 67
IP  - 5
DP  - 2015 Oct
TI  - The potential effect of the angiotensin II receptor blocker telmisartan in 
      regulating OVA-induced airway remodeling in experimental rats.
PG  - 943-51
LID - S1734-1140(15)00039-0 [pii]
LID - 10.1016/j.pharep.2015.02.010 [doi]
AB  - BACKGROUND: Bronchial asthma is a true ascending clinical problem. Angiotensin II 
      is now accused to be potentially implicated in its pathogenesis, being a potent 
      pro-inflammatory mediator with remodeling effects. OBJECTIVE: This study aims to 
      evaluate the possible protective effect of telmisartan, an angiotensin II 
      receptor blocker, on experimentally-induced bronchial asthma. METHODS: Animals 
      were divided into 5 groups; a normal control group, an asthma control group, a 
      reference treatment group, receiving dexamethasone, and two treatment groups, 
      receiving telmisartan in two dose levels. Bronchial asthma was induced by 
      intraperitoneal sensitization followed by intranasal challenge with ovalbumin 
      (OVA). Test agents were administered prior to each intranasal OVA challenge. Lung 
      function tests, namely tidal volume (TV) and peak expiratory flow rate (PEF) were 
      assessed 1h after the last challenge. One day after the last challenge, absolute 
      eosinophil counts (AEC) in blood and bronchoalveolar lavage fluids (BALF) were 
      assessed. Serum immunoglobulin E (IgE) as well as BALF total nitrate/nitrite 
      (NOx) were assessed. Oxidative and inflammatory biomarkers, namely lung tissue 
      superoxide dismutase (SOD), glutathione reduced (GSH), tumor necrosis 
      factor-alpha (TNF-alpha) and interleukin-5 (IL-5), were also assessed, in addition to 
      histopathological study. RESULTS: Telmisartan administration in both doses 
      significantly improved TV, PEF, AEC, IgE, NOx, GSH, SOD, TNF-alpha and IL-5 values 
      compared to asthma control values. Histopathological study strongly supported the 
      results of biochemical estimations, particularly regarding airway remodeling. 
      CONCLUSION: These results suggest that telmisartan may have potential protecting 
      effects against experimental bronchial asthma, probably due to its 
      bronchodilator, antioxidant and anti-inflammatory effects.
CI  - Copyright (c) 2015 Institute of Pharmacology, Polish Academy of Sciences. Published 
      by Elsevier Urban & Partner Sp. z o.o. All rights reserved.
FAU - Abdel-Fattah, Maha M
AU  - Abdel-Fattah MM
AD  - Department of Pharmacology and Toxicology, Faculty of Pharmacy, Beni-Suef 
      University, Beni-Suef, Egypt. Electronic address: dr.mahamohammed@yahoo.com.
FAU - Salama, Abeer A A
AU  - Salama AA
AD  - Department of Pharmacology, National Research Center, Giza, Egypt.
FAU - Shehata, Basim A
AU  - Shehata BA
AD  - Department of Pharmacology and Toxicology, Faculty of Pharmacy, Beni-Suef 
      University, Beni-Suef, Egypt.
FAU - Ismaiel, Ismaiel E
AU  - Ismaiel IE
AD  - Department of Pharmacology, National Research Center, Giza, Egypt.
LA  - eng
PT  - Journal Article
DEP - 20150316
PL  - Switzerland
TA  - Pharmacol Rep
JT  - Pharmacological reports : PR
JID - 101234999
RN  - 0 (Angiotensin II Type 1 Receptor Blockers)
RN  - 0 (Benzimidazoles)
RN  - 0 (Benzoates)
RN  - 0 (Biomarkers)
RN  - 0 (Serine Proteinase Inhibitors)
RN  - 9006-59-1 (Ovalbumin)
RN  - U5SYW473RQ (Telmisartan)
SB  - IM
MH  - Airway Remodeling/*drug effects
MH  - Angiotensin II Type 1 Receptor Blockers/*pharmacology
MH  - Animals
MH  - Asthma/pathology/*prevention & control
MH  - Benzimidazoles/*pharmacology
MH  - Benzoates/*pharmacology
MH  - Biomarkers
MH  - Bronchoalveolar Lavage Fluid/chemistry
MH  - Immunization
MH  - Male
MH  - Ovalbumin/*toxicity
MH  - Peak Expiratory Flow Rate/drug effects
MH  - Rats
MH  - Rats, Wistar
MH  - Respiratory Function Tests
MH  - Serine Proteinase Inhibitors/*toxicity
MH  - Telmisartan
MH  - Tidal Volume/drug effects
OTO - NOTNLM
OT  - Airway remodeling
OT  - Angiotensin II
OT  - Bronchial asthma
OT  - Rat
OT  - Telmisartan
EDAT- 2015/09/24 06:00
MHDA- 2016/07/07 06:00
CRDT- 2015/09/24 06:00
PHST- 2014/12/05 00:00 [received]
PHST- 2015/02/12 00:00 [revised]
PHST- 2015/02/23 00:00 [accepted]
PHST- 2015/09/24 06:00 [entrez]
PHST- 2015/09/24 06:00 [pubmed]
PHST- 2016/07/07 06:00 [medline]
AID - S1734-1140(15)00039-0 [pii]
AID - 10.1016/j.pharep.2015.02.010 [doi]
PST - ppublish
SO  - Pharmacol Rep. 2015 Oct;67(5):943-51. doi: 10.1016/j.pharep.2015.02.010. Epub 
      2015 Mar 16.